AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
March 05, 2024 08:52 ET
|
OPKO Health, Inc.
• Study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans• Candidate showed similar half-life to standard monoclonal...
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
February 27, 2024 16:05 ET
|
OPKO Health, Inc.
MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023. Business highlights...
OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024
February 22, 2024 16:05 ET
|
OPKO Health, Inc.
MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the...
OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes
January 09, 2024 16:05 ET
|
OPKO Health, Inc.
MIAMI, Jan. 09, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced the closing of its previously announced private offering of $230.0 million aggregate...
OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024 08:00 ET
|
OPKO Health, Inc.
MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the 42nd Annual J.P. Morgan Healthcare Conference, being held...
OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029
January 04, 2024 23:31 ET
|
OPKO Health, Inc.
MIAMI, Jan. 04, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced the pricing of its private offering of $200.0 million aggregate principal amount of its...
OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029
January 03, 2024 17:05 ET
|
OPKO Health, Inc.
MIAMI, Jan. 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (the “Company”) today announced that it is commencing a private offering of $200.0 million aggregate principal amount of its...
OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results
November 06, 2023 16:05 ET
|
OPKO Health, Inc.
MIAMI, Nov. 06, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2023. Business...
New Clinical Data on OPKO Health’s RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023
November 02, 2023 10:00 ET
|
OPKO Health, Inc.
MIAMI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) presented late-breaking clinical data on RAYALDEE® extended-release calcifediol (ERC) at the American Society of Nephrology...
OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023
October 31, 2023 08:00 ET
|
OPKO Health, Inc.
MIAMI, Oct. 31, 2023 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and nine months ended September 30, 2023 after the close of the...